Novo Nordisk has introduced an oral form of its weight-loss drug Wegovy (semaglutide), a development that may alter the competitive landscape in the UK’s obesity treatment market. The injectable version of Wegovy, which helped establish Novo Nordisk’s early lead, lost ground to Eli Lilly’s Mounjaro, but the newly approved pill could help the company regain market share, partly due to the absence of a comparable oral formulation of Mounjaro.

The oral version of semaglutide presents distinct challenges, notably poor absorption in the stomach as the active ingredient is extensively broken down by gastric juices. To compensate, the pill combines semaglutide with an absorption enhancer called SNAC and requires daily administration at doses significantly higher than those used in the injectable form. Typical dosing for the oral formulation starts at 1.5 mg daily and can increase up to 25 mg, which corresponds roughly to the 2.4 mg weekly dose used in injections.

Cost considerations may also favor the pill. While NHS access to injectable weight-loss medications remains limited and many users pay out-of-pocket, spending between £150 and £300 per month, the oral version has been advertised privately in the UK at introductory rates below £100 monthly. In the United States, where the oral Wegovy has been available since early 2026, the pill is also priced lower than its injectable counterpart.

Efficacy data, though still emerging, indicate that the oral version delivers weight loss comparable to injectable Wegovy. Clinical results show an average weight reduction between 14 and 17 percent over approximately 16 months, with about one-third of patients achieving at least 20 percent weight loss. This contrasts with Eli Lilly’s Mounjaro, which has generally been reported to produce greater weight loss, a key factor in its recent market gains.

Side effects are consistent across formulations and primarily linked to drug levels in the bloodstream rather than the method of administration. Common complaints include nausea, vomiting (slightly more frequent with the pill), gastrointestinal discomfort, and changes in bowel habits. More rare but serious adverse events such as gallbladder disease, pancreatitis, and optic neuropathy are also potential risks with both oral and injected semaglutide.

Experts welcome the availability of an oral option, citing the significant shift these medications represent in treating obesity—addressing root causes rather than only managing related conditions such as type 2 diabetes or cardiovascular disease. However, concerns remain about rapid weight loss and the potential impact on muscle and bone mass. Questions also persist regarding long-term management, as studies suggest many patients regain a substantial portion of lost weight within one to two years after discontinuing treatment, sometimes more rapidly than those relying solely on lifestyle changes.

With approximately 1.6 million UK adults already using slimming medications, the introduction of a more accessible oral semaglutide is expected to expand the market. It may especially appeal to individuals with needle phobia, which affects an estimated 10 percent of adults and can deter the use of injectable therapies.

While injectable Wegovy dosing typically involves gradual titration over weeks to months and weekly administration, the oral version requires strict adherence to daily intake on an empty stomach with minimal water. Both forms thus necessitate careful patient education to optimize outcomes.

Looking ahead, the prospect of oral semaglutide coming off patent in the 2030s raises the possibility of more affordable options reaching a broader population, potentially reshaping obesity treatment paradigms over the coming decade.